Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025Amrita Journal of MedicineOpen Access

Antibody–Drug Conjugates: Bridging Science and Therapeutics

View Full Paper
Ask AI
Bookmark
Share

Authors

KPKakoli PatnaikSiksha O Anusandhan UniversityNSNitin SharmaBirla Institute of Technology and Science, Pilani

Discussion

Loading...

Member takes

Implication

Review explores efficacy and stability of antibody–drug conjugates in targeted cancer therapy, indicating artificial intelligence may enhance drug development.

Key Points

  • Efficacy and stability improvements drive advancements in antibody–drug conjugates for cancer therapy.
  • Targeted cancer therapy utilizing antibody–drug conjugates improves drug delivery and reduces healthy tissue damage.
  • Observational analysis of recent developments highlights challenges like drug resistance and toxicity.
  • Enhancements via artificial intelligence may support future designs and improve pharmacokinetics of ADCs.

Cite This Study

Patnaik et al. (2025) studied this question.

synapsesocial.com/papers/694023f32d562116f28fda1dhttps://doi.org/10.4103/amjm.amjm_39_25
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeted Cytokine Delivery for Cancer Treatment: Engineering and Biological Effects2023 · 18 citations
  2. 2Construction of tandem diabody (IL-6/CD20)-secreting human umbilical cord mesenchymal stem cells and its experimental treatment on diffuse large B cell lymphoma2022 · 5 citations
  3. 3Chemical Modification of Proteins at Cysteine: Opportunities in Chemistry and Biology2009 · 656 citations
  4. 4Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma2016 · 204 citations
  5. 5Antibody–Drug Conjugates for Cancer Therapy2020 · 399 citations